Andere Sprachen Akili, Inc.

Aktien

AKLI

US00974B1070

AKLI

Schlusskurs Nasdaq Andere Börsenplätze 00:00:00 25.06.2024			% 5 Tage	% 1. Jan.
0,4347 ^USD	+0,16 %		+2,19 %	-10,76 %

18.06.	EndeavorOTC von Akili erhält FDA-Zulassung für ADHS-Behandlung	MT
18.06.	Akili gibt die FDA-Zulassung von EndeavorOTC bekannt, der ersten FDA-Zulassung für eine digitale Behandlung von Erwachsenen mit AdHD durch ein Videospiel	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Akili's EndeavorOTC Gets FDA Clearance For ADHD Treatment	18.06.
Akili Gets FDA Clearance for ADHD Video Game Over-the-Counter Treatment	18.06.
Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game	18.06.
Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with AdHD Through a Video Game	18.06.
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. - AKLI	05.06.
AKLI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akili, Inc. Is Fair to Shareholders	03.06.
Shareholder Alert: Ademi LLP investigates whether Akili, Inc. has obtained a Fair Price for its Public Shareholders	29.05.
PureTech Health's Akili, Virtual Therapeutics Sign Merger Deal to Launch Digital Health Company	29.05.
Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company	29.05.
Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. for $35 million.	29.05.
Akili, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Earnings Flash (AKLI) AKILI Posts Q1 Revenue $383,000, vs. Street Est of $0.8M	14.05.
Akili Reports First Quarter 2024 Financial Results and Provides Business Update	14.05.
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results	30.04.
Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	30.04.
Akili, Inc. to Reduce Workforce	30.04.
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	30.04.
Akili, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.02.
Earnings Flash (AKLI) AKILI Posts Q4 Revenue $749,000, vs. Street Est of $0.78M	29.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Akili, Inc.

Aktien

AKLI

US00974B1070

AKLI

Andere Sprachen

Filter